miRNA changes mediate therapeutic resistance by a wide set of oncogenic interactions including resistance to apoptosis, inhibition of metabolic regulatory genes (namely FOXO1), and notably the upregulation of AR in prostate cancer, providing a direct link to castration resistance [73,76]. This evidence concerns the gene AR and prostate carcinoma.